Rituximab is more effective than second anti-TNF therapy in rheumatoid arthritis patients and previous TNFα blocker failure
Joern Kekow,1 Ulf Mueller-Ladner,2 Hendrik Schulze-Koops3
1Clinic of Rheumatology and Orthopedics, Otto-von-Guericke University of Magdeburg, Vogelsang-Gommern; 2Department of Rheumatology and Clinical Immunology, Kerckhoff Clinic, Bad Nauheim; 3Division of Rheumatology, University of Munich, Munich, Germany
Purpose: To assess the efficacy of one course of rituximab (two 1-g doses) compared to an alternative tumor necrosis factor-α (TNFα) blocker in rheumatoid arthritis patients who had experienced one previous TNFα blocker failure (eg, etanercept, adalimumab, or infliximab).
Patients and methods: The efficacy of both treatments was studied in this retrospective, multicenter, noninterventional cohort study with 196 patients. All patients had active rheumatoid arthritis defined by a Disease Activity Score-28 of ≥3.2 despite having TNFα blocker therapy, and were followed over 6.6 months on average after switching to rituximab versus a second TNFα blocker (ie, switching to etanercept, adalimumab, or infliximab) at baseline.
Results: At baseline, both cohorts showed similar demographic and disease-related characteristics (including Disease Activity Score-28). At the end of observation, mean Disease Activity Score-28 was significantly lower after treatment with rituximab than with a second TNFα blocker (-1.64 [95% confidence interval: -1.92; -1.36] versus -1.19 [95% confidence interval: -1.42; -0.96], P = 0.013). This difference between the two groups was even more pronounced when patients were seropositive for rheumatoid factor (-1.66 versus -1.17, P = 0.018) and anti-cyclic citrullinated peptide antibodies (-1.75 versus -1.06, P = 0.002). More rituximab-treated patients achieved good European League Against Rheumatism response than TNFα blocker-treated patients (30% versus 15%), and less patients were nonresponders (22% versus 35%) according to European League Against Rheumatism criteria (P = 0.022, chi-squared test).
Conclusion: Treatment with rituximab was more effective than a second TNFα blocker therapy in rheumatoid arthritis patients after failure of the first TNFα blocker. It was found that anti-cyclic citrullinated peptide antibodies may be a useful predictive biomarker for response to rituximab in patients with TNFα blocker treatment failure.
Keywords: rheumatoid arthritis, rituximab, anti-cyclic citrullinated peptide antibodies, rheumatoid factor
This work is published by Dove Medical Press Limited, and licensed under Creative Commons Attribution - Non Commercial (unported, v3.0) License. The full terms of the License are available at http://creativecommons.org/licenses/by-nc/3.0/. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. Permissions beyond the scope of the License are administered by Dove Medical Press Limited. Information on how to request permission may be found at: http://www.dovepress.com/permissions.php
Readers of this article also read:
Sarah Horton, Maya H Buch, Paul Emery
Published Date: 17 August 2010
Effect of biologic therapy on radiological progression in rheumatoid arthritis: what does it add to methotrexate?
Jones G, Darian-Smith E, Kwok M, Winzenberg T
Published Date: 2 July 2012
First-line treatment of EGFR-mutant non-small-cell lung cancer: the role of erlotinib and other tyrosine kinase inhibitors
Nguyen KS, Neal JW
Published Date: 25 September 2012
Chang MR, Goswami D, Mercer BA, Griffin PR
Published Date: 12 October 2012
Efficacy of ipamorelin, a ghrelin mimetic, on gastric dysmotility in a rodent model of postoperative ileus
Greenwood-Van Meerveld B, Tyler K, Mohammadi E, Pietra C
Published Date: 23 October 2012
Effectiveness of nootropic drugs with cholinergic activity in treatment of cognitive deficit: a review
Colucci L, Bosco M, Ziello AR, Rea R, Amenta F, Fasanaro AM
Published Date: 12 December 2012
Systematic review and network meta-analysis of combination and monotherapy treatments in disease-modifying antirheumatic drug-experienced patients with rheumatoid arthritis: analysis of American College of Rheumatology criteria scores 20, 50, and 70
Orme ME, MacGilchrist KS, Mitchell S, Spurden D, Bird A
Published Date: 17 December 2012
Ansari J, Hussain SA, Ansari A, Glaholm J
Published Date: 28 February 2013
Factors correlated with improvement of endothelial dysfunction during rituximab therapy in patients with rheumatoid arthritis
Benucci M, Saviola G, Manfredi M, Sarzi-Puttini P, Atzeni F
Published Date: 15 March 2013
Keller-von Amsberg G, Schafhausen P
Published Date: 6 May 2013